EGFR and non-small cell lung carcinoma: Recent randomised trials demonstrated that the presence of an EGFR activating mutation was the best predictive factor for response and progression-free survival (PFS) to EGFR TKIs when compared to platinum doublet chemotherapy in the first-line therapy of advanced NSCLC [6],[7].